Atlas Genetics announces positive results from the first US Chlamydia trachomatis beta study
05 January 2017
Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the Point-Of-Care (POC) molecular diagnostics company, today announces positive results from a United States beta study for Chlamydia trachomatis (CT) on its rapid io® diagnostic platform.
Marinus Provides Business Outlook for 2017
05 January 2017
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business overview to outline the clinical status of its CNS-selective GABAA modulator, ganaxolone, and an overview of near-term value-creating milestones expected in 2017.
Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent
05 January 2017
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 15/086,485 entitled, “Methods and Devices for the Treatment of Ocular Diseases in Human Subjects.”
Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors
05 January 2017
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Pierre Legault, MBA, CA, CPA to its board of directors.
Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer
04 January 2017
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the appointment of Richard L. Beckman , M.D. to the position of Chief Medical Officer.
03 January 2017
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its CNS-selective GABAA modulator, ganaxolone, for the treatment of Fragile X Syndrome (FXS).
Feel the Earth Move Under Your Brand?
29 December 2016
It’s a new year with new forecasts, wise prognostications, and sage extrapolations informed by last year’s rear view mirror. They’re often insightful. Sometimes misguided. Always interesting.
Personalized Medicine Needs Personalized Marketing
29 December 2016
According to Grand View Research, the global personalized medicine market was valued at more than $1 billion in 2014 and is expected to reach almost $2.5 billion in 2022, a CAGR of 11.8 percent over the forecast period.
Holding out for a pharma M&A rebound in 2017? It may be a while
28 December 2016
If there’s one word that describes 2016’s pharma M&A market, it’s “slow.” And while some industry watchers predict that the new year—and administration—could bring a jolt of energy to the dealmaking arena, no one’s expecting big changes fast.
With billions at stake, will biosims finally make a mark in the U.S. in 2017?
28 December 2016
Biosimilars have already taken hold in Europe, with Celltrion's Remicade copy, for one, wreaking havoc on the branded med's sales. Whether they'll finally make their mark in the U.S., though, remains to be seen—and 2017 could be the year we find out.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024